Skip to main content
NB

Ningaloo Biosystems

Ningaloo Biosystems develops a cyber bioproduction platform that uses light-based technology to precisely modulate the activity of production cells in bioreactors. This synthetic biology approach provides real-time control over bioprocesses, enabling scalable and sustainable manufacturing of complex biopharmaceuticals. The platform aims to lower prohibitive production costs, thereby increasing patient access to advanced, life-saving medicines.

Köln, GermanyFounded 2020
Updated 4 months ago

Funding

$4.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Producing complex biopharmaceuticals at scale is challenging due to limited control over cellular processes, resulting in high production costs and variability in product quality. Traditional biomanufacturing methods lack the real-time precision needed to optimize cell-based production of next-generation biological medicines.

Solution

Ningaloo Biosystems offers cyber bioproduction solutions that use optogenetics to convert cells into light-controlled bioproduction systems, enabling real-time control over cellular processes. Their technology allows biopharma companies to use photons to precisely control product output, protein activity and quality, and purity while reducing side products. By implementing photoswitches inside living cells, Ningaloo's platform allows for optical control of membrane potentials, cellular signal transduction, protein translocation, and gene expression. This approach enhances the efficiency, reliability, and scalability of complex biopharmaceutical manufacturing, paving the way for advanced curing options in areas such as cancer, immunology, gene therapy, and neurodegenerative disease therapies.

Target Audience

Ningaloo Biosystems serves biopharmaceutical companies, contract development and manufacturing organizations (CDMOs), and research laboratories focused on developing and producing complex biotherapeutics.

Features

  • Optogenetic tools for light-mediated control of cellular functions
  • DEL-VPR photoswitch system for light-dose-dependent gene expression
  • MLA-1 laboratory device for controlling cultured cells with light
  • Wireless connectivity via Bluetooth for remote operation
  • High dynamic range of light intensities for precise control
  • Pre-calibrated light intensities for consistency across experiments
  • Interchangeable light guides compatible with 6, 24, and 96-well formats
  • Intuitive software for ease of use and electronic documentation
This profile is AI-generated and may contain inaccuracies.